Development of cell-based assays to measure botulinum neurotoxin serotype a activity using cleavage-sensitive antibodies

Journal of Biomolecular Screening

Volumn 15, Issue 1, 2010, Pages 52-61

  Nuss, Jonathan E ^a   Ruthel, Gordon ^a   Tressler, Lyal E ^a   Wanner, Laura M ^a   Torres Melendez, Edna ^a   Hale, Martha L ^a   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

Assay development; Botulism; Cell based assay; Drug discovery; High throughput screening

Indexed keywords

ANTITOXIN; BABYBIG; BOTULINUM TOXIN A; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; NEUROTOXIN; SNARE PROTEIN; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; ASSAY; BINDING AFFINITY; BOTULISM; CELL BASED ASSAY; CHICKEN; CONTROLLED STUDY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; IMMUNOFLUORESCENCE; MOTONEURON; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SPINAL CORD; WESTERN BLOTTING;

EID: 77949354718     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057109355319     Document Type: Article

References (23)

1. Ting PT, Freiman A: The story of Clostridium botulinum: from food poisoning to Botox. Clin Med 2004 4 258-261.
2. Turton K, Chaddock JA, Acharya KR: Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002 27 552-558.
3. Kreyden OP, Geiges ML, Boni R, Burg GG: Botulinum toxin: from poison to drug. An historical review. Hautarzt 2000 51 733-737.
4. Botulism associated with commercially canned chili sauce-Texas and Indiana. Morb Mortal Wkly Rep 2007 56 767-769.
5. Domingo RM, Haller JS, Gruenthal M: Infant botulism: two recent cases and literature review. J Child Neurol 2008 23 1336-1346.
6. Fox CK, Keet CA, Strober JB: Recent advances in infant botulism. Pediatr Neurol 2005 32 149-154.
7. Godeiro-Junior C, Felicio AC, Aguiar PC, Borges V, Silva SM, Ferraz HB: Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients. Can J Neurol Sci 2009 36 222-226.
8. Madalinski M, Kalinowski L: Novel options for the pharmacological treatment of chronic anal fissure: role of botulin toxin. Curr Clin Pharmacol 2009 4 47-52.
9. Sun-Edelstein C, Mauskop A: Complementary and alternative approaches to the treatment of tension-type headache. Curr Pain Headache Rep 2008 12 447-450.
10. Young WB, Marmura M, Ashkenazi A, Evans RW: Expert opinion: Greater occipital nerve and other anesthetic injections for primary headache disorders. Headache 2008 48 1122-1125.
11. Dembek ZF, Kortepeter MG, Pavlin JA: Discernment between deliberate and natural infectious disease outbreaks. Epidemiol Infect 2007 135 353-371.
12. Burnett JC, Henchal EA, Schmaljohn AL, Bavari S: The evolving field of biodefence: therapeutic developments and diagnostics. Nat Rev Drug Discov 2005 4 281-297.
13. Tseng-Ong L, Mitchell WG: Infant botulism: 20 years' experience at a single institution. J Child Neurol 2007 22 1333-1337.
14. Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC: Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998 5 898-902.
15. Dressier D, Adib Saberi F: Botulinum toxin: mechanisms of action. Eur Neurol 2005 53 3-9.
16. Brunger AT, Breidenbach MA, Jin R, Fischer A, Santos JS, Montai M: Botulinum neurotoxin heavy chain belt as an intramolecular chaperone for the light chain. PLoS Pathog 2007 3 1191-1194.
17. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, et al: Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993 365 160-163.
18. Schiavo G, Rossetto O, Catsicas S, Polverino de Laureto P, DasGupta B, et al: Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 1993 268 23784-23787.
19. Stahl AM, Ruthel G, Torres-Melendez E, Kenny TA, Panchal RG, Bavari S: Primary cultures of embryonic chicken neurons for sensitive cell-based assay of botulinum neurotoxin: implications for therapeutic discovery. J Biomol Screen 2007 12 370-377.
20. Kuhn TB: Growing and working with spinal motor neurons. Methods Cell Biol 2003 71 67-87.
21. Pless DD, Torres ER, Reinke EK, Bavari S: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect Immun 2001 69 570-574.
22. Schmidt JJ, Stafford RG: Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol 2003 69 297-303.
23. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, et al: An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA 2007 104 2602-2607.